(thirdQuint)Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer.

 This is a multi-center, open-label, Phase I study with an expansion cohort, in patients with metastatic Castrate-Resistant Prostate Cancer (CRPC) who are chemotherapy-naive or have previously received docetaxel chemotherapy and have progressive disease at the time of study entry.

 The dose escalation phase of this study will establish the optimum daily dose of everolimus that can be delivered along with a standard daily dose of enzalutamide to patients with metastatic CRPC.

 Eligible patients must have evaluable (elevated PSA) or measurable disease (per RECIST v1.

1).

 Following completion of the dose escalation phase, an additional cohort of patients will be treated at the maximum tolerated dose (MTD) to give preliminary information regarding the efficacy of this combination.

.

 Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer@highlight

The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never received prior chemotherapy, or who have previously received docetaxel chemotherapy and have progressive disease.

